Business

Biopharma Market Reaction

Updated 2026-09-08 14:10 UTC 1 source Negative

Novartis's failed cholesterol drug trial has led to a broader selloff in the biopharmaceutical sector. The company had hoped this would reduce cardiovascular risks.

Coverage timeline — 1 article

MarketWatch

Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

2026-09-08 13:53 UTC